EconPapers has moved to http://EconPapers.repec.org! Please update your bookmarks.
From Astra-Zeneca to Pfizer: When Protection of OriginatorsÃ¢â‚¬â„¢ Patents Ceases to be a Ã¢â‚¬Å“RightÃ¢â‚¬Â and Becomes an Abuse of Dominance
, 2012, vol. 7
Antitrust Chronicle Abstract:
National agencies do not refrain from dealing with sensitive and critical mattersÃ¢â‚¬â€such as the interplay between IP and antitrust lawÃ¢â‚¬â€which one would assume the EU Commission would be primarily addressing. Stefano Grassani (Pavia e Ansaldo)
JEL-codes: G38 (search for similar items in EconPapers)
References: Add references at CitEc Citations Track citations by RSS feed
Downloads: (external link) http://www.competitionpolicyinternational.com/from ... n-abuse-of-dominance (application/pdf)
Requires login and subscription
Related works: This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: http://EconPapers.repec.org/RePEc:cpi:atchrn:7.2.2012:i=7747
Access Statistics for this article
More articles in Antitrust Chronicle from Competition Policy International
Series data maintained by Lindsay McSweeney ().